Pathway Genomics Corporation Appoints Former Cedars-Sinai Medical Center Chair Of Medicine Glenn D. Braunstein, M.D., As Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, has announced that endocrinologist Dr. Glenn D. Braunstein is the company's new Chief Medical Officer. Dr. Braunstein takes on the role after serving on Pathway Genomics' Strategic Advisory Board. With a special interest in pharmacogenomics, Dr. Braunstein's first priority will be Pathway Genomics' pharmacogenomic testing menu.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.